PharmaSGP Holding SE

Total Valuation

PharmaSGP Holding SE carries a market capitalization of 333.86M, placing it among publicly traded companies globally. Its enterprise value stands at 253.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

PharmaSGP Holding SE currently has 11.51M shares outstanding.

Valuation Ratios

PharmaSGP Holding SE trades at a trailing price-to-earnings ratio of 14.28. The price-to-sales ratio is 2.31, and the price-to-book ratio stands at 30.90.

Enterprise Valuation

On an enterprise value basis, PharmaSGP Holding SE trades at an EV/EBITDA multiple of 8.99 and an EV/FCF ratio of 9.56. The EV/Sales ratio of 2.07 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.99 provides insight into valuation relative to core operating earnings.

Financial Position

PharmaSGP Holding SE maintains a current ratio of 2.68, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.35, indicating elevated leverage, while an interest coverage ratio of 7.65 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

PharmaSGP Holding SE posts a return on equity of 265.88 and a return on invested capital of 47.33.

Taxes

Over the trailing twelve months, PharmaSGP Holding SE has paid 6.59M in income taxes, reflecting an effective tax rate of 25.06.

Stock Price Statistics

PharmaSGP Holding SE's stock has gained approximately 51.04167% over the past 52 weeks. The 50-day moving average sits at 28.52, while the 200-day moving average is 26.10.

Income Statement

Over the trailing twelve months, PharmaSGP Holding SE generated 122.10M in revenue and converted that into 19.71M in net income, yielding earnings per share of 1.71. EBITDA reached 28.15M, while operating income came in at 28.15M.

Balance Sheet

PharmaSGP Holding SE holds 29.32M in cash and equivalents against 860,000.00 in total debt, resulting in a net debt position of -29.32M. Total book value stands at 9.11M, with working capital of 37.44M providing operational flexibility.

Cash Flow

PharmaSGP Holding SE produced 22.18M in operating cash flow over the past twelve months. After subtracting -1.53M in capital expenditures, free cash flow totaled 20.65M - equivalent to 1.79 per share.

Margins

PharmaSGP Holding SE operates with a gross margin of 90.55, reflecting its pricing power and cost economics. The operating margin of 23.06 and net profit margin of 16.14 provide insight into operational efficiency.

Dividends & Yields

Scores

PharmaSGP Holding SE posts an Altman Z-Score of 6.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.